Equities

Captor Therapeutics SA

Captor Therapeutics SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)74.20
  • Today's Change-2.20 / -2.88%
  • Shares traded162.00
  • 1 Year change-36.58%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in PLN

The 3 analysts offering 12 month price targets for Captor Therapeutics SA have a median target of 131.00, with a high estimate of 135.00 and a low estimate of 70.00. The median estimate represents a 76.55% increase from the last price of 74.20.
High81.9%135.00
Med76.5%131.00
Low-5.7%70.00

Earnings history & estimates in PLN

Captor Therapeutics SA reported annual 2023 losses of -15.19 per share on Apr 09, 2024.
Average growth rate-47.25%
More ▼

Revenue history & estimates in PLN

Captor Therapeutics SA had 2nd quarter 2024 revenues of 4.80m. This missed the 7.00m estimate of the one analyst following the company. This was 210.76% above the prior year's 2nd quarter results.
Average growth rate+31.41%
Captor Therapeutics SA had revenues for the full year 2023 of 13.20m. This was 44.15% above the prior year's results.
Average growth rate+86.95%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.